FDA clears Ventana's image analysis app for cancer detection

Ventana Medical Systems has been granted 510(k) clearance to go to market with an image analysis application used to detect breast and other types of cancer. The Ventana Companion HER2 (4B5) application assists pathologists with interpretation of images of a certain protein in tissue, according to a company statement.

Also receiving clearance was a Ventana application that allows digital reading of slides stained with the same protein. Both applications work with the company’s Virtuoso software and iScan Coreo Au scanner.

Oro Valley, Ariz.-based Ventana is owned by the Swiss pharmaceutical firm Roche.

 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.